ArticleNature communications2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Pooled it
- Predicting IDH and ATRX mutations in gliomas from radiomic features with machine learning: a systematic review and meta-analysis.Frontiers in radiology · 2024Pooled it
- Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.Nature medicine · 2026Trial
- DNA Methylation Profiling in IDH-Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation.Neuropathology and applied neurobiology · 2026Review
- IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma.Nature communications · 2026Article
- Notch Overexpression Potentiates Interferon Signaling in Glioma Cells.Current issues in molecular biology · 2026Article
- Humanized Murine Glioblastoma Models for Evaluation of Coxsackievirus Oncolytic Therapy.Cancers · 2026Article
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
- Establishment of Centrosome Amplification-Correlated Model to Evaluate the Tumor Immune Microenvironment and Prognosis of Patients with Glioblastoma.Current medicinal chemistry · 2026Article
- Functional analysis of telomere maintenance mechanisms is more informative than immunohistochemistry for ATRX mutation interpretation in Gliomas.Acta neuropathologica communications · 2025Article
- Advances in the management of patients with IDH-mutant glioma.The oncologist · 2025Review
- TCA cycle-derived oncometabolites in cancer and the immune microenvironment.Journal of biomedical science · 2025Review
- Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025Review
- OncoImmune machine-learning model predicts immune response and prognosis in leiomyosarcoma.Biomolecules & biomedicine · 2025Article
- Panoramic spatial enhanced resolution proteomics (PSERP) reveals tumor architecture and heterogeneity in gliomas.Journal of hematology & oncology · 2025Article
- Deep visual proteomics reveals DNA replication stress as a hallmark of signet ring cell carcinoma.NPJ precision oncology · 2025Article
- Implications of molecular classifications in glioma surgery.Journal of neuro-oncology · 2025Review
- The Gender-Biased Differential Effect ofCancers · 2025Article
- Prognostic and predictive determinants in high-grade gliomas: integrating tumor-intrinsic biology with patient and system-level factors.Frontiers in neurology · 2025Review
- Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment.Oncology research · 2025Review
Corrections and comments
- Update of
Authors and funding
27 authors at 4 institutions in 1 country.
Seethalakshmi Hariharan *The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Benjamin T Whitfield *Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2624-8464
Christopher J PirozziThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Matthew S WaitkusThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-7116-6978
Michael C BrownThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Michelle L BowieThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
David M IrvinDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kristen RosoThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Rebecca FullerThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Janell HostettlerThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Sharvari DharmaiahDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emiley A GibsonThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID 0009-0008-5570-2233
Aaron BrileyThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Avani MangoliThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-1695-9983
Casey FraleyThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Mariah ShobandeThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Kevin StevensonThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Gao ZhangThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-8617-8886
Prit Benny MalgulwarDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9393-1055
Hannah RobertsDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Martin RoskoskiThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Ivan SpasojevicPK/PD Core Laboratory, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-9890-6246
Stephen T KeirThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Yiping HeThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Maria G CastroDepartment of Neurosurgery, University of Michigan Medical Center, Ann Arbor, MI, USA.
Jason T HuseDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jhuse@mdanderson.org.
David M AshleyThe Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. david.ashley@duke.edu.ORCID 0000-0002-4754-5900
Duke Medical Center · USThe University of Texas MD Anderson Cancer Center · USDuke University · USUniversity of Michigan · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MConvalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3MNRSA Training CoreTL1TR003169 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHANDRA, JOYA, FROST, JEFFREY A. · 2019 to 2023
$3.7MATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomasR01CA255788 · NCI · DUKE UNIVERSITY · PI WAITKUS, MATTHEW · 2022 to 2025
$1.9MCharacterizing heterochromatin dysfunction as a driving alteration in cancerR01CA240338 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUSE, JASON · 2019 to 2023
$1.8MNCATS NIH HHS TL1 TR003169NCATS NIH HHS UL1 TR003167NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA240338NCI NIH HHS R01 CA255788
Abstract
Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional immune signaling. However, little is known about the interplay between ATRX loss and IDH mutation on innate immunity. To explore this, we generated ATRX-deficient glioma models in the presence and absence of the IDH1
Indexed as
AstrocytomaBrain NeoplasmsGliomaHumansImmunity, InnateIsocitrate DehydrogenaseMutationX-linked Nuclear ProteinATRX protein, humanIDH1 protein, humanIsocitrate DehydrogenaseX-linked Nuclear Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.